Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Biopharmaceutics permeability classification of lorcaserin, a selective 5-hydroxytryptamine 2C agonist: method suitability and permeability class membership.

Chen C, Ma MG, Fullenwider CL, Chen WG, Sadeque AJ.

Mol Pharm. 2013 Dec 2;10(12):4739-45. doi: 10.1021/mp400468c. Epub 2013 Oct 29.

PMID:
24102111
2.

Time-dependent inhibition and estimation of CYP3A clinical pharmacokinetic drug-drug interactions using plated human cell systems.

Albaugh DR, Fullenwider CL, Fisher MB, Hutzler JM.

Drug Metab Dispos. 2012 Jul;40(7):1336-44. doi: 10.1124/dmd.112.044644. Epub 2012 Apr 9.

PMID:
22490230
3.

Characterization of aldehyde oxidase enzyme activity in cryopreserved human hepatocytes.

Hutzler JM, Yang YS, Albaugh D, Fullenwider CL, Schmenk J, Fisher MB.

Drug Metab Dispos. 2012 Feb;40(2):267-75. doi: 10.1124/dmd.111.042861. Epub 2011 Oct 26.

PMID:
22031625
4.

Aryl 1,4-diazepane compounds as potent and selective CB2 agonists: optimization of drug-like properties and target independent parameters.

Zindell R, Walker ER, Scott J, Amouzegh P, Wu L, Ermann M, Thomson D, Fisher MB, Fullenwider CL, Grbic H, Kaplita P, Linehan B, Patel M, Patel M, Löbbe S, Block S, Albrecht C, Gemkow MJ, Shih DT, Riether D.

Bioorg Med Chem Lett. 2011 Jul 15;21(14):4276-80. doi: 10.1016/j.bmcl.2011.05.068. Epub 2011 May 27.

PMID:
21689933

Supplemental Content

Loading ...
Support Center